Prescient rises 60 pc following successful AML trial
Prescient Therapeutics (PTX) shares rose 60 per cent this morning after expanding its Phase 1b...
Prescient Therapeutics (PTX) shares rose 60 per cent this morning after expanding its Phase 1b...
Cancer drug developer Prescient Therapeutics (ASX: PTX) is expanding its Phase 1b study in patients with acute...
This week we were joined in office by Prescient Therapeutics (ASX: PTX) CEO and Managing...
Humankind has been trying to find a cure for cancer for thousands of years. Today,...
Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company which is engaged in small molecule drug...
Oncology company Prescient Therapeutics (ASX: PTX) has unveiled a potentially lucrative collaboration with Adelaide-based Carina Biotech to...
Prescient Therapeutics has entered a collaboration with Carina Biotech to develop new targeted cell therapies...
Stockhead’s resident Health and Biotech expert Tim Boreham is coming to you live from the 2019...
With a focus on addressing mutations causing cancer, Prescient Therapeutics Limited (ASX: PTX) develops personalised medicines as potential...
Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company focused on developing personalised medicines as potential novel...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.